Skip main navigation

Military Health System

Clear Your Browser Cache

This website has recently undergone changes. Users finding unexpected concerns may care to clear their browser's cache to ensure a seamless experience.

Mid-Season Influenza Vaccine Effectiveness Estimates Among DOD Populations: A Composite of Data Presented at VRBPAC—the Vaccines and Related Biological Products Advisory Committee—2024 Meeting on Influenza Vaccine Strain Selection for the 2024-2025 Influenza Season

Image of 48088663. The Department of Defense participates in the annual Vaccines and Related Biological Products Advisory Committee meeting by presenting its mid-season influenza data.

Each March, the Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Agency meets to review and discuss data on influenza strain circulation and vaccine effectiveness estimates for the current influenza season.1 The committee then makes recommendations on the selection of strains for the influenza vaccines to be developed for the following influenza season. 

The Department of Defense participates in the VRBPAC meeting by presenting mid-season influenza data from the DOD’s global influenza surveillance, VE, and phylogenetic analyses, in addition to antigenic characterization of circulating viruses. DOD VE analyses are conducted among both service member and non-service member beneficiary populations to complement U.S. population VE estimates.2 

Timing of these analyses is dependent upon the timing of peak activity for each season. Typically, mid-season estimates cannot be generated until February, to allow for adequate testing and sufficient case numbers to provide a reliable sample size for analysis.

These DOD VE analyses represent a joint effort between the Defense Health Agency's Defense Centers for Public Health in Falls Church and Dayton and the Naval Health Research Center. The combined assessment of data from these organizations provides the DOD, FDA, and U.S. Centers for Disease Control with comprehensive mid-season information on how well the influenza vaccines are working for force health protection and the broader military health population. 

MSMR anticipates publishing these findings annually, in February or March, to disseminate this information more widely to interested individuals and public health agencies. 

Author Affiliations

Epidemiology and Analysis Branch, Armed Forces Health Surveillance Division, Defense Health Agency: Dr. Eick-Cost, Ms. Hu; Defense Centers for Public Health–Dayton, Defense Health Agency: Mr. Thervil, Ms. DeMarcus 

Disclaimer

The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views, assertions, opinions, nor policies of the Defense Health Agency or the Department of Defense. 

References

  1. U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-may-16-2024-meeting-announcement 
  2. McLean HQ, Petrie JG, Hanson KE, et al. Interim estimates of 2022-23 seasonal influenza vaccine effectiveness–Wisconsin, October 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023;72:201-205.

You also may be interested in...

Report
Sep 1, 2023

MSMR Vol. 30 No. 9 - September 2023

.PDF | 1.30 MB

The September 2023 MSMR provides the annual update of routine screening for antibodies to HIV among the active and reserve components of the U.S. Armed Forces; followed by a serological survey of Ross River virus (RRV) infection among U.S. Marine expeditionary forces who train in Australia; followed by a Surveillance Snapshot of the 10 leading ...

Article
Sep 1, 2023

Update: Routine Screening for Antibodies to Human Immunodeficiency Virus, U.S. Armed Forces, Active and Reserve Components, January 2018–June 2023

This report provides an update through June 2023 of routine screening results for antibodies to HIV among members of the U.S. military. From January 2018 through June 2023, approximately 7 million U.S. military service members (active component, reserve component, and national guard) were tested for HIV antibodies; 1,502 were identified as HIV ...

Report
Aug 1, 2023

MSMR Vol. 30 No. 8 - August 2023

.PDF | 1.02 MB

The August 2023 MSMR provides the most recent data from the active surveillance program for acute respiratory disease and Group A Beta-Hemolytic Streptococcus among U.S. Army basic trainees; then summarizes the case report of an extensively resistant E. coli in a returning traveler at Hawai'i's Tripler Army Medical Center; followed by a Surveillance ...

Article
Aug 1, 2023

Case Report: Complicated Urinary Tract Infection Due to an Extensively Resistant Escherichia coli in a Returning Traveler

This article presents the medical case report of a 76-year-old man who returned to the U.S. following overseas travel and was admitted at Hawai'i's Tri­pler Army Medical Center with a complicated urinary tract infection due to an extensively resistant strain of E. coli.

Article
Aug 1, 2023

Active Surveillance for Acute Respiratory Disease Detected No Outbreaks at Four U.S. Army Basic Training Installations in 2022

This article presents the 2022 results of the active surveillance program for acute respiratory disease and Group A Beta-Hemolytic Streptococcus conducted by the Defense Centers for Public Health-Aberdeen at the four Army installations responsible for basic combat training or one-station unit training. This ARD surveillance program rapidly monitors, ...

Report
Jul 1, 2023

MSMR Vol. 30 No. 7 - July 2023

.PDF | 1.30 MB

This continuation of the June issue, which published the annual quantification of health care provided by the Military Health System, continues with the impacts of various illnesses and injuries in 2022 among deployed service members; medical evacuations out of theaters of military operation; health care provision to non-service member MHS ...

Skip subpage navigation
Refine your search
Last Updated: May 07, 2024
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Sign up on GovDelivery